Condition category
Nutritional, Metabolic, Endocrine
Date applied
22/04/2016
Date assigned
26/04/2016
Last edited
26/04/2016
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Trained dogs are increasingly being used to detect when people with type 1 diabetes have low blood sugar (glucose). No one knows how well these dogs work, yet patients are paying tens of thousands of dollars to purchase dogs from dog trainers. Doctors don't know what to tell their patients about the dogs because we don't know enough about them. The aim of this study is to find out how reliable trained dogs are at detecting low blood sugar levels. We will compare the dog alerts to blood sugar measurement tools that are already well-tested: fingerstick blood tests and a continuous glucose monitoring (CGM) device.

Who can participate?
Type 1 diabetes patients aged 2-80 who already use a trained dog to detect low blood sugar levels

What does the study involve?
The study lasts one week. Participants go about their usual lives while wearing a "blinded" CGM which measures glucose levels but the numbers are not visible to the participant. When their dog alerts, the participant carries out a fingerstick blood test and records any low blood sugar symptoms. Participants also complete a brief survey about low blood sugar and how well they think their dog works.

What are the possible benefits and risks of participating?
Participants will receive a copy of the CGM report at the end of their participation and will be paid for their time. Possible risks include problems with the CGM insertion including pain, bleeding or infection at the insertion site, or discomfort with extra fingerstick blood tests.

Where is the study run from?
Oregon Health & Science University (USA)

When is the study starting and how long is it expected to run for?
June 2014 to August 2015

Who is funding the study?
Jaeb Center For Health Research (USA)

Who is the main contact?
Dr Evan Los

Trial website

Contact information

Type

Scientific

Primary contact

Dr Evan Los

ORCID ID

http://orcid.org/0000-0002-7567-0178

Contact details

Mail Code: CDRC-P
707 SW Gaines Street
Portland
97239
United States of America

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

OHSU IRB00010881; Jaeb Center for Health Research PPQ#10061006829

Study information

Scientific title

Reliability of trained dogs to detect hypoglycemia in patients with type 1 diabetes

Acronym

Study hypothesis

1. Trained dogs will not be able to reliably detect and alert to hypoglycemia in patients with type 1 diabetes
2. Compared to a continuous glucose monitor (CGM) with established reliability data, trained dogs will provide inferior detection and alert capabilities in patients with type 1 diabetes
3. Trained dogs accurately alert to rate of change and absolute glucose values

Ethics approval

Oregon Health & Science University Institutional Review Board, approved 31/03/2015, renewed 27/11/2015, IRB#00010881

Study design

Pilot study exploring the test characteristics (sensitivity, positive predictive value) of a trained dog to detect hypoglycemia under real-life conditions. The study also explores patient perceptions of dog reliability and subjective value.

Primary study design

Interventional

Secondary study design

Non randomised study

Trial setting

Home

Trial type

Diagnostic

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Type 1 diabetes

Intervention

Use of trained dog to detect and alert to hypoglycemia events. We assess and compare accuracy to measurement tools with known accuracy - capillary glucose and continuous glucose monitoring. Continuous glucose monitors are blinded to allow for detection of unrecognized hypoglycemia (by either subject or trained dog). Detailed event diaries allow assessment of dog alerts and compare to time stamp of continuous glucose monitor measurement and capillary blood glucose.

Intervention type

Other

Phase

Drug names

Primary outcome measures

1. Rate of correct identification and alert to hypoglycemia event by trained dog:
1.1. Rate of correct alert (CBG or CGM <70 mg/dL and dog alert prior to other measures)
1.2. Rate of delayed alert (CBG or CGM <70 mg/dL and dog alert after other measures)
1.3. Rate of missed alert (CBG or CGM <70 mg/dL and no dog alert)
1.4. Rate of incorrect alert (alert without the presence of hypoglycemia)

Secondary outcome measures

1. Mean and median time to alert after CGM <70
2. Rate of change of CGM value at time of dog alert
3. Total duration of time with CGM value <70 mg/dL per 24 hours)
4. Subjective confidence of dog’s master in the trained dog’s ability to detect hypoglycemia
5. Rate of hypoglycemia events for which dog is not present/not available
6. Rate of correct identification and alert to hyperglycemia event by trained dog at threshold designated by dog’s master

Overall trial start date

01/06/2014

Overall trial end date

19/08/2015

Reason abandoned

Eligibility

Participant inclusion criteria

Age 2-80 years with diagnosis of type 1 diabetes and current user of dog formally trained to detect hypoglycemia

Participant type

Patient

Age group

All

Gender

Both

Target number of participants

Originally targeted 15 subjects to gather 45 hypoglycemia events. Target number of events achieved after 8 subjects. Interim power analysis showed additional subjects would not provide additional statistical power so enrollment stopped at 8 subjects

Participant exclusion criteria

1. Pregnancy
2. Unwilling to use blinded CGM device
3. Inability to speak, read, write and understand English language

Recruitment start date

01/06/2015

Recruitment end date

19/08/2015

Locations

Countries of recruitment

United States of America

Trial participating centre

Oregon Health & Science University
97239
United States of America

Sponsor information

Organisation

Jaeb Center for Health Research (USA)

Sponsor details

15310 Amberly Drive Ste. 350
Tampa
33647
United States of America

Sponsor type

Research organisation

Website

https://www.jaeb.org/

Funders

Funder type

Research organisation

Funder name

Jaeb Center For Health Research (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Oral presentation of study findings at American Diabetes Association 76th Scientific Sessions; New Orleans, Louisiana; June 2016.
Anticipate submission of manuscript of study results in May/June 2016.

Intention to publish date

01/06/2016

Participant level data

Available on request

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes